© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The German pharmaceutical company Boehringer Ingelheim has ceased development of its investigatory hepatitis C drug faldaprevir.
Faldaprevir and deleobuvir plus Presidio’s PPI-668 cured 92 percent of those with genotype 1a of hepatitis C virus when given with riba...
Researchers presented findings from clinical trials of hepatitis C therapies at the 2014 Conference on Retroviruses and Opportunistic...
Deleobuvir is out of the running in the mad dash to bring new hepatitis C virus (HCV) drugs to the market.
Faldaprevir, deleobuvir and PPI-668 showed high promise in curing genotype 1a of hepatitis C virus in early trial results.
Faldaprevir and deleobuvir, plus ribavirin, cured genotype 1 of hepatitis C virus (HCV) in 52 to 69 percent of study participants in a recent...
Faldaprevir and deleobuvir (BI 207127), plus ribavirin, cured 95 percent of the participants with genotype 1b of hepatitis C virus in a Phase...
Faldaprevir with pegylated interferon and ribavirin cured about 80 percent of treatment-naive people with genotype 1 of hepatitis C in a Phase...
At the recent Conference on Retroviruses and Opportunistic Infections researchers reveled in promising new data on hepatitis C therapies.
Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early succ...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
